Business
INmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4
Management to host conference call and webcast at 4:30 pm ET on that day LA JOLLA, Calif, Feb. 25, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB)
About this update from Inmune Bio Inc.
[{"type":"text","content":"Management to host conference call and webcast at 4:30 pm ET on that day LA JOLLA, Calif, Feb. 25, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Thursday, March 4, 2021 at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2020 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Fourth Quarter Conference Call when reaching an operator. Date: March 4, 2021 Time: 4:30 PM Eastern Time Participant Dial-in: 1-877-407-0784Participant Dial-in (international): 1-201-689-8560Live Webcast Link: http://public.viavid.com/index.php?id=143196 A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through March 11, 2021 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 13715561. About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. Information about Forward-Looking Statements Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-loo...